Results 41 to 50 of about 419,158 (294)

The Patient’s Perspective on Psoriatic Arthritis: What More Can Rheumatologists Do to Optimise Disease Management?

European Medical Journal Rheumatology, 2017
The symposium at the European League Against Rheumatism (EULAR) 2017 congress aimed to provide insights into the burden of psoriatic arthritis (PsA) on patients’ daily lives, including the significant impact of unresolved musculoskeletal symptoms, and ...
Pfizer
doaj  

Assessment of Some Immunological Parameters Postvaccination with Different Types of COVID-19 Vaccines

Medical Journal of Babylon
Background: Coronavirus disease 2019 (COVID-19) is a highly contagious viral infection that can spread rapidly worldwide. Several vaccines have been developed to combat COVID-19.
Haneen Saad Khasbak, Hayder Shkhair Al-Janabi, Mohanad Jawad Kadhim   +2 more
doaj   +1 more source

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

Dermatology and Therapy, 2023
Introduction Alopecia areata (AA) is an autoimmune disease with an underlying immuno-inflammatory pathogenesis. Treatments can include systemic corticosteroids and immunomodulators (such as Janus kinase inhibitors); these medications may be associated ...
Prethibha George, Oladayo Jagun, Qing Liu, Charles Wentworth, Lynne Napatalung, Robert Wolk, Susan Anway, Samuel H. Zwillich   +7 more
doaj   +1 more source

Federal Asbestos Legislation: The Winners Are ... [PDF]

, 2005
Under the guise of providing aid to victims of asbestos-related illnesses, a small group of companies has lobbied for and won relief from their liability worth tens of billions of dollars in the Senate's asbestos trust fund bill, according to this Public
Chris Schmitt, Frank Clemente
core  

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. [PDF]

, 2014
BackgroundIn the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone ...
Baselga, J, Bauly, H, Burris, HA, Chouinard, E, Csoszi, T, Eakle, J, El-Hashimy, M, Feng, W, Geberth, M, Gnant, M, Hortobagyi, G, Noguchi, S, Perez, A, Piccart, M, Pritchard, KI, Puttawibul, P, Rugo, HS, Srimuninnimit, V, Taran, T   +18 more
core   +1 more source

Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling

FEBS Open Bio, EarlyView.
Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero, Maria Kopsida, Nathalie Arendt, Hans Lennernäs, Markus Sjöblom, Femke Heindryckx   +5 more
wiley   +1 more source

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

Infectious Diseases and Therapy, 2020
Introduction Widespread use of ten-valent (Synflorix™, GSK) or 13-valent (Prevenar 13™; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not contained within the
Sarah Pugh, Matt Wasserman, Margaret Moffatt, Susana Marques, Juan Manuel Reyes, Victor A. Prieto, Davy Reijnders, Mark H. Rozenbaum, Juha Laine, Heidi Åhman, Raymond Farkouh   +10 more
doaj   +1 more source

Stroke with unknown time of symptom onset: baseline clinical and magnetic resonance imaging data of the first thousand patients in WAKE-UP (efficacy and safety of mri-based thrombolysis in wake-up stroke: a randomized, doubleblind, placebo-controlled trial) [PDF]

, 2017
Background and Purpose—We describe clinical and magnetic resonance imaging (MRI) characteristics of stroke patients with unknown time of symptom onset potentially eligible for thrombolysis from a large prospective cohort.
Boutitie, Florent, Cheng, Bastian, Cho, Tae-Hee, Ebinger, Martin, Endres, Matthias, Fiebach, Jochen B., Fiehler, Jens, Ford, Ian, Galinovic, Ivana, Gerloff, Christian, Lemmens, Robin, Muir, Keith W., Nighoghossian, Norbert, Pedraza, Salvador, Puig, Josep, Roy, Pascal, Simonsen, Claus Z., Thijs, Vincent, Thomalla, Götz   +18 more
core   +2 more sources

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source

Predicting Loss of Ambulation in Limb Girdle Muscular Dystrophy R9

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Limb girdle muscular dystrophy type R9 (LGMDR9) results from biallelic variants in FKRP. There is limited data to predict loss of ambulation (LOA) among those with LGMDR9. Methods Participants in an ongoing dystroglycanopathy natural history study (NCT00313677) with FKRP variants who had achieved ambulation and were more than 3 ...
Chandra L. Miller, Lauren N. Coffey, Shelley R. H. Mockler, Katie M. Laubscher, Carrie M. Stephan, M. Bridget Zimmerman, Katherine D. Mathews   +6 more
wiley   +1 more source